CD8A and melanoma: Double PD-1 and TIGIT inhibition enhances tumor antigen-specific CD8+ T cell expansion and activity in vitro, and increases proliferation and function of tumor antigen-specific CD8+ T cells and tumor infiltrating lymphocytes (TILs) isolated from patients with melanoma, as compared with single inhibition [32].